1
Home
Companies

Puma Biotechnology

Puma Biotechnology
Leadership team

Mr. Alan H. Auerbach (Founder, Chairman, Pres, CEO & Sec.)

Mr. Maximo F. Nougues (CFO & Principal Accounting Officer)

Dr. Alvin F. Wong Pharm.d. (Chief Scientific Officer)

Products/ Services
Biotechnology, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Los Angeles, California, United States
Established
2010
Company Registration
SEC CIK number: 0001401667
Net Income
5M - 20M
Revenue
100M - 500M
Traded as
NASDAQ:PBYI
Social Media
URL
https://www.pumabiotechnology.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
History

Puma Biotechnology, Inc. was founded in August 2010 and is a publicly traded biopharmaceutical company based in Los Angeles, California. The company focuses on developing and commercializing innovative cancer therapies and its first approved product is Nerlynx (neratinib).

Mission
Puma Biotechnology seeks to empower cancer patients by developing and commercializing novel therapeutics and novel drugs for cancer dose optimization that improve patient outcomes.
Vision
Puma Biotechnology will provide innovative therapeutics to improve the lives of cancer patients and their families.
Key Team

Mr. Jeffrey Jerome Ludwig (Chief Commercial Officer)

Mr. Douglas Hunt B.Sc., FRAPS (Sr. VP of Regulatory Affairs, Medical Writing & Project Management)

Mr. Mariann Ohanesian (Sr. Director of Investor Relations)

Recognition and Awards
In 2016, Puma Biotechnology was awarded the American Society of Clinical Oncology Clinical Investigator of the Year Award and was named the 2016 Red Herring Top 100 Global award winner. The company was also awarded the 2017 Prix Galien USA Special Recognition Award for Best Overall Industry Contribution.
References

https://en.wikipedia.org/wiki/Puma_Biotechnology

https://in.investing.com/equities/puma-biotechnlgy

https://finance.yahoo.com/quote/PBYI/profile?p=PBYI

https://www.crunchbase.com/organization/puma-biotechnology

https://www.pumabiotechnology.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Puma Biotechnology
Leadership team

Mr. Alan H. Auerbach (Founder, Chairman, Pres, CEO & Sec.)

Mr. Maximo F. Nougues (CFO & Principal Accounting Officer)

Dr. Alvin F. Wong Pharm.d. (Chief Scientific Officer)

Products/ Services
Biotechnology, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Los Angeles, California, United States
Established
2010
Company Registration
SEC CIK number: 0001401667
Net Income
5M - 20M
Revenue
100M - 500M
Traded as
NASDAQ:PBYI
Social Media
URL
https://www.pumabiotechnology.com